However, as the main transcription factor in IL-17-expressing immune cells, RORγ has been investigated in various cancer cells and tumor-infiltrating cells (Figure 1), indicating that it might be a promising prognostic factor in lung and BC and a potential therapeutic target in prostate cancer. Here, IL17A is linked to breast cancer.